Literature DB >> 6980356

Evaluation of bone mass and growth in young diabetics.

P S Wiske, S M Wentworth, J A Norton, S Epstein, C C Johnston.   

Abstract

To determine the relationships among bone mass, bone growth and serum glucose control in young, insulin-dependent diabetics, we performed photon absorptiometry and radiogrammetry on a clinically well-characterized group of 78 diabetics (mean age 15.2 yr, mean duration of diabetes 6.7 yr). Total and ionized calcium (TCa, ICa), magnesium (Mg), immunoreactive parathyroid hormone (iPTH) and phosphorus (P) were measured in fasting serum. Bone age was calculated from hand x-rays; and bone measurements, heights, and weights were standardized against normal groups of corresponding age, sex, and race. Mean deviation of bone mass measurement score was 1.24 SD below the normal mean (p less than .001); mean cortical area score was .22 SD and percent cortical area .25 SD below the normal means (both p less than .05). Radical width and metacarpal width for the diabetics were not less than normal. Mean percentiles for height and weight were 52.3 and 57.1 respectively, the latter significantly elevated (p less than .02). Bone mass and cortical area were inversely related to duration of disease (r = -.228, p less than .05; r = -.216, p less than .05). They were not correlated with serum parameters of mineral metabolism or of glucose control. Bone age was not significantly different from chronological age in those who had not achieved maturity (14.4 versus 14.5 yr). Mean age of menarche was 12.9 yr. When compared to normals the diabetic sample had diminished serum ICa (p less than .001), and Mg (p less than .001), though P and iPTH were not significantly different. We have demonstrated: (1) bone mass in this sample of juvenile diabetics is depressed, without evidence of impaired overall growth or delayed maturation, (2) this reduced bone mass probably results from a failure to gain the normal component of endosteal bone expected at this age, (3) this abnormality in bone growth progresses with disease but does not appear to vary with serum glucose control, and (4) in this population of diabetics there is a minimal but significant reduction in serum total and ionized calcium and serum magnesium without compensatory elevation of parathyroid hormone. The relationship of this metabolic abnormality of impaired bone growth in unknown.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6980356     DOI: 10.1016/0026-0495(82)90086-5

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  15 in total

Review 1.  Osteoporosis and diabetes mellitus.

Authors:  Angela M Inzerillo; Solomon Epstein
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

2.  Diabetic bone disease.

Authors:  R Bouillon
Journal:  Calcif Tissue Int       Date:  1991-09       Impact factor: 4.333

3.  Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.

Authors:  T Shibata; S Takeuchi; S Yokota; K Kakimoto; F Yonemori; K Wakitani
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

4.  Effects of advanced glycation end-products on the proliferation and differentiation of osteoblast-like cells.

Authors:  A D McCarthy; S B Etcheverry; L Bruzzone; A M Cortizo
Journal:  Mol Cell Biochem       Date:  1997-05       Impact factor: 3.396

5.  Possible mechanism of inhibition of cartilage alkaline phosphatase by insulin.

Authors:  C Gazzarrini; N Stagni; P Pollesello; P D'Andrea; B De Bernard
Journal:  Acta Diabetol Lat       Date:  1989 Oct-Dec

6.  Height at diagnosis of insulin dependent diabetes in patients and their non-diabetic family members.

Authors:  T J Songer; R E LaPorte; N Tajima; T J Orchard; B S Rabin; M S Eberhardt; J S Dorman; K J Cruickshanks; D E Cavender; D J Becker
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-31

Review 7.  Skeletal growth and bone mineral acquisition in type 1 diabetic children; abnormalities of the GH/IGF-1 axis.

Authors:  Manish Raisingani; Brar Preneet; Brenda Kohn; Shoshana Yakar
Journal:  Growth Horm IGF Res       Date:  2017-04-28       Impact factor: 2.372

8.  Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice.

Authors:  Sergiu Botolin; Marie-Claude Faugere; Hartmut Malluche; Michael Orth; Ron Meyer; Laura R McCabe
Journal:  Endocrinology       Date:  2005-05-19       Impact factor: 4.736

9.  Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk.

Authors:  P Vestergaard; L Rejnmark; L Mosekilde
Journal:  Diabetologia       Date:  2005-05-21       Impact factor: 10.122

10.  Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications.

Authors:  P Pietschmann; G Schernthaner; W Woloszczuk
Journal:  Diabetologia       Date:  1988-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.